Trillium Asset Management LLC Has $614,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Key Points

• Trillium Asset Management LLC significantly reduced its stake in Hologic, Inc. by 90% in the first quarter, now holding just 9,943 shares worth approximately $614,000.
• Several other institutional investors, including Public Sector Pension Investment Board and AIA Group Ltd, have increased their positions in Hologic, highlighting a diverse interest among hedge funds.
• Hologic's earnings report surpassed expectations, with a reported $1.08 EPS for the quarter and a revenue of $1.02 billion, marking a 1.2% increase year-over-year.

Trillium Asset Management LLC reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 90.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 9,943 shares of the medical equipment provider's stock after selling 89,620 shares during the period. Trillium Asset Management LLC's holdings in Hologic were worth $614,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter valued at about $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Hologic during the first quarter worth about $42,000. Raiffeisen Bank International AG acquired a new position in shares of Hologic in the fourth quarter valued at approximately $49,000. Allworth Financial LP raised its position in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the last quarter. Finally, Larson Financial Group LLC grew its holdings in Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 722 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Morgan Stanley upped their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. UBS Group upped their price target on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $77.83.

Hologic Stock Down 0.4%

Shares of NASDAQ HOLX traded down $0.25 during mid-day trading on Friday, reaching $67.81. The company had a trading volume of 4,294,477 shares, compared to its average volume of 1,738,030. The stock has a fifty day moving average of $65.60 and a two-hundred day moving average of $62.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market capitalization of $15.08 billion, a price-to-earnings ratio of 28.14, a PEG ratio of 2.46 and a beta of 0.49. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm earned $1.06 earnings per share. The firm's revenue was up 1.2% compared to the same quarter last year. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.